 In 2019 esketamine, an NMDA antagonist enantiomer of ketamine, was approved for use as an antidepressant in the United States.Although NMDA antagonists were once thought to reliably cause neurotoxicity in humans in the form of Olney's lesions, recent research suggests otherwise.Olney's lesions involve mass vacuolization of neurons observed in rodents.